Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Amyloid-β(1-15/16) as a m… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.

Artikel i vetenskaplig tidskrift
Författare Erik Portelius
Henrik Zetterberg
Robert A Dean
Alexandre Marcil
Philippe Bourgeois
Magdalena Nutu
Ulf Andreasson
Eric Siemers
Kwasi G Mawuenyega
Wendy C Sigurdson
Patrick C May
Steven M Paul
David M Holtzman
Kaj Blennow
Randall J Bateman
Publicerad i Journal of Alzheimer's disease : JAD
Volym 31
Nummer/häfte 2
Sidor 335-41
ISSN 1875-8908
Publiceringsår 2012
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 335-41
Språk en
Länkar dx.doi.org/10.3233/JAD-2012-120508
Ämnesord Adult, Alanine, analogs & derivatives, pharmacology, Alzheimer Disease, cerebrospinal fluid, diagnosis, enzymology, Amyloid Precursor Protein Secretases, antagonists & inhibitors, metabolism, Amyloid beta-Peptides, cerebrospinal fluid, Azepines, pharmacology, Biological Markers, cerebrospinal fluid, Cohort Studies, Double-Blind Method, Humans, Male, Middle Aged, Peptide Fragments, cerebrospinal fluid, Protease Inhibitors, pharmacology, Single-Blind Method, Young Adult
Ämneskategorier Neurokemi

Sammanfattning

Amyloid-β (Aβ) producing enzymes are key targets for disease-modifying Alzheimer's disease (AD) therapies since Aβ trafficking is at the core of AD pathogenesis. Development of such drugs might benefit from the identification of markers indicating in vivo drug effects in the central nervous system. We have previously shown that Aβ(1-15) is produced by concerted β-and α-secretase cleavage of amyloid-β protein precursor (AβPP). Here, we test the hypothesis that this pathway is more engaged upon γ-secretase inhibition in humans, and cerebrospinal fluid (CSF) levels of Aβ(1-15/16) represent a biomarker for this effect. Twenty healthy men were treated with placebo (n = 5) or the γ-secretase inhibitor semagacestat (100 mg [n = 5], 140 mg [n = 5], or 280 mg [n = 5]). CSF samples were collected hourly over 36 hours and 10 time points were analyzed by immunoassay for Aβ(1-15/16), Aβ(x-38), Aβ(x-40), Aβ(x-42), sAβPPα, and sAβPPβ. The CSF concentration of Aβ(1-15/16) showed a dose-dependent response over 36 hours. In the 280 mg treatment group, a transient increase was seen with a maximum of 180% relative to baseline at 9 hours post administration of semagacestat. The concentrations of Aβ(x-38), Aβ(x-40), and Aβ(x-42) decreased the first 9 hours followed by increased concentrations after 36 hours relative to baseline. No significant changes were detected for CSF sAβPPα and sAβPPβ. Our data shows that CSF levels of Aβ(1-15/16) increase during treatment with semagacestat supporting its feasibility as a pharmacodynamic biomarker for drug candidates aimed at inhibiting γ-secretase-mediated AβPP-processing.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?